Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer

Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer

Objective: c-Met is expressed in human ovarian cancer tissues, and its phosphorylation activates signaling cascades that might affect the behavior of cancer cells. In this study, we evaluated the association of c-Met and phosphorylated c-Met (phospho-c-Met) expressions with the clinical outcomes of...

Full description

Bibliographic Details
Main Authors:	Ling Lim, Chao-Chih Wu, Yun-Ting Hsu, Fang-Ju Sun, Chih-Long Chang
Format:	Article
Language:	English
Published:	Elsevier 2019-01-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455918302948

Similar Items

Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET
by: Chao-Chih Wu, et al.
Published: (2019-01-01)

Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
by: Huimin Wang, et al.
Published: (2015-02-01)

Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer
by: Sun W, et al.
Published: (2013-09-01)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
by: Huang L, et al.
Published: (2020-08-01)

Structure–activity relationship of antioxidant dipeptides: Dominant role of Tyr, Trp, Cys and Met residues
by: Lin Zheng, et al.
Published: (2016-03-01)

Expression of c-MET in Invasive Meningioma
by: Sumi Yun, et al.
Published: (2015-01-01)

Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses
by: Stephan Wilmes, et al.
Published: (2021-04-01)

Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis
by: Jifeng Peng, et al.
Published: (2016-01-01)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
by: Yong Chul Kim, et al.
Published: (2018-08-01)

An overview of the c-MET signaling pathway
by: Shawna Leslie Organ, et al.
Published: (2011-11-01)

Studies on the human c-Met receptor
by: Sirulnik, Leonardo Andres
Published: (1995)

c-Met and miRs in Cancer
by: Simona Giglio, et al.
Published: (2015-01-01)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
by: Haiyan Liao, et al.
Published: (2021-09-01)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
by: Huilai Lv, et al.
Published: (2015-01-01)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
by: Liang H, et al.
Published: (2020-03-01)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
by: Daniel Martin Klotz, et al.
Published: (2021-09-01)

1,2,3,5-Tetrahydronaphtho[2,1-c]oxepine
by: Alan J. Lough, et al.
Published: (2020-03-01)

Structural basis of the activation of c-MET receptor
by: Emiko Uchikawa, et al.
Published: (2021-07-01)

HGF/c-MET Signaling in Melanocytes and Melanoma
by: Malgorzata Czyz
Published: (2018-12-01)

Research progress in c-Met and hepatocellular carcinoma
by: WANG Changqing
Published: (2015-06-01)

Expression of c-met in canine mammary tumors
by: Ying-Yu Chen, et al.
Published: (2016)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
by: Nam Ah Kim, et al.
Published: (2020-02-01)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
by: Birgit Lohberger, et al.
Published: (2021-06-01)

The novel roles of c-Met and Lutheran in bladder cancer formation
by: Chen-Yun Yeh, et al.
Published: (2005)

Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation
by: Shunyao Xu, et al.
Published: (2020-07-01)

miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer
by: Yang S, et al.
Published: (2020-04-01)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
by: Qingyun Yuan, et al.
Published: (2021-01-01)

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
by: Sameer A Greenall, et al.
Published: (2012-01-01)

The significance of an achondroplasia-like condition met with in cattle
by: Crew, F. A. E.
Published: (1923)

HGF and c-Met interaction promotes migration in human chondrosarcoma cells.
by: Hsi-Kai Tsou, et al.
Published: (2013-01-01)

Targeting HGF/c-MET Axis in Pancreatic Cancer
by: Srinivasa P. Pothula, et al.
Published: (2020-12-01)

Future directions in the evaluation of c-MET-driven malignancies
by: Johann S. de Bono, et al.
Published: (2011-11-01)

c-MET: an exciting new target for anticancer therapy
by: Johann S. de Bono, et al.
Published: (2011-11-01)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
by: Haiyu Wang, et al.
Published: (2020-02-01)

Role of cMET in the Development and Progression of Colorectal Cancer
by: Ilaria Bossi, et al.
Published: (2013-09-01)

The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma
by: Luis J. Herrera, et al.
Published: (2005-01-01)

Efficacy of c-Met inhibitor for advanced prostate cancer
by: Christensen James G, et al.
Published: (2010-10-01)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
by: Neeta K. Venepalli, et al.
Published: (2013-01-01)

Diskussie met J. C. Kruger: Die begrippe
by: J. v.V. du Plessis
Published: (1982-06-01)

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma
by: Joycelyn J. X. Lee, et al.
Published: (2015-10-01)